Baidu
map

ACC2011:阵发性房颤合并高血压的患者的左心房直径和房颤发生频率

2011-05-07 MedSci原创 MedSci原创

     背景:众所周知,左心房直径(LAD)和房颤的发病率相关。但是,LAD与房颤发生频率的关系仍不得而知。     方法:选取J-RHYTHM II研究中的288名患者,这项随机临床研究的目的是比较CCB和ARB在日本阵发性房颤合并高血压的患者中的治疗效果。LAD的基本结果在心彩超下按标准模式测量得出。在

     背景:众所周知,左心房直径(LAD)和房颤的发病率相关。但是,LAD与房颤发生频率的关系仍不得而知。     方法:选取J-RHYTHM II研究中的288名患者,这项随机临床研究的目的是比较CCB和ARB在日本阵发性房颤合并高血压的患者中的治疗效果。LAD的基本结果在心彩超下按标准模式测量得出。在电话传输心电图下记录28天中房颤发生的频率。采用单变量和多变量线性回归分析评价LAD和房颤发生天数的关系。根据LAD和房颤发生天数将患者分为4组,进行ANOVA比较,并计算95%可信区间(CI)。     结果:LAD与房颤发生的天数相关,LAD每增加10mm,房颤发生天数就增加1.9天(95% CI 0.9-2.8)。在对年龄、性别以及其他可能的混淆因素进行调整后,这一关系仍然成立。平均房颤发生天数与LAD四分位数成线性增长的关系。     结论:在阵发性房颤合并高血压的患者中,LAD与房颤发生天数增加

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1659689, encodeId=5df01659689c9, content=<a href='/topic/show?id=da5c480e024' target=_blank style='color:#2F92EE;'>#左心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48070, encryptionId=da5c480e024, topicName=左心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50dc25016902, createdName=ylz8411, createdTime=Fri Jul 15 16:32:00 CST 2011, time=2011-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324738, encodeId=be801324e388c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon May 09 01:32:00 CST 2011, time=2011-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423515, encodeId=fcda1423515cd, content=<a href='/topic/show?id=a1a69e630b5' target=_blank style='color:#2F92EE;'>#阵发性房颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97630, encryptionId=a1a69e630b5, topicName=阵发性房颤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36783798280, createdName=lqrandywkz, createdTime=Mon May 09 01:32:00 CST 2011, time=2011-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626767, encodeId=05e01626e6769, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon May 09 01:32:00 CST 2011, time=2011-05-09, status=1, ipAttribution=)]
    2011-07-15 ylz8411
  2. [GetPortalCommentsPageByObjectIdResponse(id=1659689, encodeId=5df01659689c9, content=<a href='/topic/show?id=da5c480e024' target=_blank style='color:#2F92EE;'>#左心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48070, encryptionId=da5c480e024, topicName=左心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50dc25016902, createdName=ylz8411, createdTime=Fri Jul 15 16:32:00 CST 2011, time=2011-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324738, encodeId=be801324e388c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon May 09 01:32:00 CST 2011, time=2011-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423515, encodeId=fcda1423515cd, content=<a href='/topic/show?id=a1a69e630b5' target=_blank style='color:#2F92EE;'>#阵发性房颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97630, encryptionId=a1a69e630b5, topicName=阵发性房颤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36783798280, createdName=lqrandywkz, createdTime=Mon May 09 01:32:00 CST 2011, time=2011-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626767, encodeId=05e01626e6769, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon May 09 01:32:00 CST 2011, time=2011-05-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1659689, encodeId=5df01659689c9, content=<a href='/topic/show?id=da5c480e024' target=_blank style='color:#2F92EE;'>#左心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48070, encryptionId=da5c480e024, topicName=左心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50dc25016902, createdName=ylz8411, createdTime=Fri Jul 15 16:32:00 CST 2011, time=2011-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324738, encodeId=be801324e388c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon May 09 01:32:00 CST 2011, time=2011-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423515, encodeId=fcda1423515cd, content=<a href='/topic/show?id=a1a69e630b5' target=_blank style='color:#2F92EE;'>#阵发性房颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97630, encryptionId=a1a69e630b5, topicName=阵发性房颤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36783798280, createdName=lqrandywkz, createdTime=Mon May 09 01:32:00 CST 2011, time=2011-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626767, encodeId=05e01626e6769, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon May 09 01:32:00 CST 2011, time=2011-05-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1659689, encodeId=5df01659689c9, content=<a href='/topic/show?id=da5c480e024' target=_blank style='color:#2F92EE;'>#左心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48070, encryptionId=da5c480e024, topicName=左心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50dc25016902, createdName=ylz8411, createdTime=Fri Jul 15 16:32:00 CST 2011, time=2011-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324738, encodeId=be801324e388c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon May 09 01:32:00 CST 2011, time=2011-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423515, encodeId=fcda1423515cd, content=<a href='/topic/show?id=a1a69e630b5' target=_blank style='color:#2F92EE;'>#阵发性房颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97630, encryptionId=a1a69e630b5, topicName=阵发性房颤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36783798280, createdName=lqrandywkz, createdTime=Mon May 09 01:32:00 CST 2011, time=2011-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626767, encodeId=05e01626e6769, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon May 09 01:32:00 CST 2011, time=2011-05-09, status=1, ipAttribution=)]
    2011-05-09 sodoo

相关资讯

房颤治疗指南更新有依据

(作者刘少稳教授)   房颤治疗策略历来存在节律控制与心率控制之争,美国心脏病学会基金会(ACCF)/美国心脏学会(AHA)/美国心律学会(HRS)2011和欧洲心脏病学会(ESC)2010更新版房颤治疗指南均指出,控制心率的益处主要是改善房颤患者症状,而非改善预后,对于症状不明显的房颤患者而言,严格的心率控制甚至有害。   房颤心率控制范围尚无共识 关于房颤患者心率控制目标,因循证

ACC2011:迷走神经节消融治疗长期持续性房颤

     背景:迷走神经节消融(GP)对长期持续性房颤患者的治疗效果仍未明确。     方法:89名有症状、药物治疗无效的持续性房颤患者接受左心房迷走神经节区域的解剖消融(男性71名;年龄56±7)。之后29名患者接受环肺静脉隔离术的二次消融,其中5名患者进行第三次CPVI。   

ACC2011:在有不同类型的房颤患者中比较达比加群酯与华法林:一项RE-LY亚组分析

  背景:RE-LY试验将18 113例有房颤和至少有一项卒中危险因素的患者随机分配接受达比加群酯(110 mg或150 mg,bid)或调整剂量的华法林。  方法:来自RE-LY试验的一项亚组分析在有不同类型的房颤患者中评估了与华法林相比达比加群酯的有效性和安全性。  结果:共有18 107例患者有房颤类型的详情;6375例为永久性房颤,5943例为阵发性房颤,5789例为持续性房颤。在永久性房

ACC2011:导管消融对阵发性房颤发展的影响

目的:确定射频消融对阵发性房颤发展的影响。 背景:50%的阵发性房颤接受药物治疗后可能发展为持续性房颤。高血压,年龄,既往短暂性缺血性时间,慢性阻塞性肺疾病和心力衰竭(HATCH评分)均被确立为房颤发展的独立危险因素。 方法:504名房颤患者(年龄58±10岁)接受RFA治疗以消除阵发性房颤。193名患者(38%)接受再次消融手术。采用多因素分析评估各临床因素对RFA后结果的预测价值以及它们与房颤

心脏术后预防房颤如何选择?

来源:中国医学论坛报   β受体阻滞剂?胺碘酮?    对于预防心脏手术后心房颤动(AF)发生,现有指南推荐β受体阻滞剂为一线药物,当患者经β受体阻滞剂治疗无效或存在禁忌证时,才应使用胺碘酮治疗。尽管指南做出此种推荐,但一项在加拿大医生中进行的调查显示,当前仍有19%的医生将胺碘酮作为预防术后AF发生的一线药物。为此,芬兰学者12月 7日在《内科学年鉴》[Ann Intern M

RACE Ⅱ符合临床实际,房颤治疗观念应更新

(作者马长生教授)   10年前, AFFIRM研究发现房颤心率控制和节律控制对患者预后作用相似,颠覆了之前几十年房颤治疗中反复复律并依赖副作用严重的抗心律失常药物维持窦性心律的错误治疗策略。房颤药物治疗由此进入了首选心率控制时代。   研究未见严格控制心率有益 房颤患者最佳心率控制范围并不明确, ACC/AHA/ESC 2006 房颤指南建议

Baidu
map
Baidu
map
Baidu
map